Investor focus is intensifying on upcoming U.S. inflation data, which holds potential implications for Federal Reserve rate ...
Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback